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Abstract
 Humira, an anti-TNF drug aimed at decreasing inflammation in Rheuma-
toid Arthritis patients, can cause skin diseases from rashes to skin cancer. Humira 
works by blocking the chemical receptor RANKL which inhibits the production 
of osteoclasts. Osteoclasts are cells that attack and eat bone and cartilage there-
fore an inhibitory mechanism would cause inflammation.. By analyzing Hu-
mira’s effect on the human body, Humira can be compared to other treatments 
such as electro-acupuncture and pulsatile dry cupping to determine  the viability 
of these alternative treatment methods in regards to their abilities to decrease 
inflammation in Rheumatoid Arthritis patients through blocking RANKL. An 
analysis of these treatment methods can also be used to determine the safest 
treatment method..  Under close examination of scientific journals written on 
studies where patients and animals were treated with Humira, acupuncture, and 
cupping for inflammation due to arthritis, the data collected suggests that Hu-
mira, electro-acupuncture, and pulsatile dry cupping  all decrease inflammation 
in the joints of Rheumatoid Arthritis patients. However, acupuncture causes the 
least harmful side-effects, with nausea and localized tingling being the most com-
mon complaints. On the other hand, localized bruising is caused by cupping and 
Humira is associated to an increased risk of cancer, heart failure and liver failure. 
Therefore, electro-acupuncture and pulsatile dry cupping are  safer alternatives 
to Humira for the treatment of inflammation associated with Rheumatoid Ar-
thritis. As a result, the data collected from this review supports that acupuncture 
has the same therapeutic effects as Humira, but is less deleterious and an overall 
better treatment method to Rheumatoid Arthritis compared to Humira. 
Introduction
 Rheumatoid Arthritis (RA) is a form of arthritis that leads to the inflam-
mation of joints and is often associated with joint pain. RA specifically affects 
paired joints, joints found on both sides of the body such as the wrists, hips, and 
knees. Currently RA affects about 1% of the American population and is more 
prevalent in women than in men. Current research indicates that “pain is the 
second most common cause of loss of work in the United States”  (Kim 135). 
Therefore, there has been incentive to develop  new drugs that treat the joint 
inflammation and pain characteristic of RA. Drugs  have been effective because 
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various drugs can be synthesized from a wide array of compounds to treat differ-
ent types of ‘pain’ in specific areas of the human body. As a result, the medical 
field has turned to drugs to solve many issues related to the body, including RA. 
However, according to Kim (2004), “with all the advances of technology and 
treatments, it [pain] still remains a major problem in our society and continues 
to worsen”  (135). Kim’s statement suggests that drug treatments for pain may 
be minimally effective in terms of treating the ‘pain’  that Americans feel on a 
daily basis. Thus alternative treatment options, must also be considered when 
providing a treatment plan for a patient. Alternative treatments include utiliz-
ing alternative medicine, which is comprised of  Traditional Chinese Medicine 
(TCM), a combination of “herbal remedies and acupuncture are the treatments 
most commonly used by TCM practitioners,” (National Institute of Health 1) 
along with other forms of mind-body medicine that do not solely rely on drugs. 
Acupuncture, a form of TCM, has been practiced in China since before  second 
century B.C., and has been used for centuries to cure pain. Today, “TCM is now 
practiced in one form or another by more than 300,000 practitioners in over 140 
countries” (Scheid 10) and is taught in some European colleges, allowing TCM 
treatments to be available to many people throughout the United States, Europe, 
and Asia. Furthermore, new technology, in combination with these  TCM treat-
ments, has produced new forms of remedies such as electro-acupuncture, which 
provides an electric impulse to the needle while acupuncture is being performed, 
and pulsatile dry cupping, which “is a modernized technology using a mechani-
cal device that generates a pulsatile vacuum with a pump,”  (Teut 2). 
 Treatments for the joint inflammation caused by RA requires TNF reduc-
tion. Humira is one of the most common drugs and it is used as a treatment for 
RA due to its ability to reduce TNF at high levels.  While the prescription drug 
Humira has high levels of TNF reduction, the side effects, especially “increased 
risk for developing serious infections that may lead to hospitalization or death” 
(Physician’s Desk Reference 1), can lead to infections such as Tuberculosis and 
an increased risk of cancer. These adverse reactions make Humira less desirable 
then the alternative therapies of electro-acupuncture and pulsatile dry cupping, 
whose side-effects include, “nausea or small tingling pain where the needle was 
injected ” (Ouyang 508), and localized bruising. Furthermore, Humira is the 
most expensive treatment to have for one year, compared to acupuncture and 
pulsatile dry cupping (Food and Drug Administration 1).   In addition,, even 
though Humira can be directly delivered to a patient through the mail and thus 
is easy to acquire, there is a growing number of facilities that offer acupuncture 
and cupping(Alderman B5). Also, of the three treatment methods, acupunc-
ture is the most readily available treatment method because it is offered in every 
state, whereas the other two are not. Due to the less severe side effects associat-
ed with electro-acupuncture compared to Humira and the greater prevalence of 
2A U C T U S  // VCU’s Journal of Undergraduate Research and Creativity // STEM // April 2015
electro-acupuncture compared to pulsatile dry cupping, this review of research 
supports electro-acupuncture as the best choice for patients to reduce their in-
flammation and pain  caused by Rheumatoid Arthritis. 
Inflammation Due To Rheumatoid Arthritis
 As stated above, RA currently affects about 1% of the American popu-
lation, and is more prevalent in women than in men. One explanation is that 
women experience osteoporosis at a much high rate compared to men, resulting 
in greater bond damage. Inflammation in the joints is a symptom of RA, and is 
often treated with drugs, acupuncture, and/or cupping. In order to treat RA, the 
process that causes inflammation has to first be analyzed and studied.  
 According to G. Jie, a doctor at Suzhou Hospital of Traditional Medicine 
in China , et al. “TNF-α [a form of TNF] is an important physiological media-
tor of inflammation that mediates the host inflammatory response and leads to 
tissue damage, and is one of the most active inflammatory factors in RA” (207). 
This is further supported by Ouyang et al. in “Effect of Electro-acupuncture on 
Tumor Necrosis Factor-α and Vascular Endothelial Growth Factor in Peripheral 
Blood and Joint Synovia of Patients with Rheumatoid Arthritis.” (2011)  The re-
searchers stated that “it is well-known that high levels of tumor necrosis factor-α 
(TNF-α) and vascular endothelial growth factor (VEGF) could be detected in 
blood serum or joint synovia of patients with rheumatoid arthritis (RA)” (505). 
This supports the notion that higher TNF levels are always found when there is 
an increase in inflammation. These findings show that TNF and inflammation 
have a directly proportional relationship to each other and that any treatment 
that lowers inflammation should also lower the TNF levels in a patient’s body. 
 In a study on how TNF is related to osteoclast production, “Tumor Ne-
crosis Factor Receptor-associated Factor 6 is an Intranuclear Transcriptional Co-
activator in Osteoclasts,” by Bai et al. (2008) , Bai et al. reported that “RANK 
is a member of the tumor necrosis factor (TNF) receptor superfamily, and as 
such, its cytoplasmic domain binds a number of TNF receptor-associated fac-
tors (TRAFs)” (30861). Since TNF and RANK have similar enough chemical 
structures they both activate RANKL, the cytoplasmic receptor of RANK. This 
is further supported in in, “Changes in Bone Mineral Density During Long-term 
Treatment with Adalimumab in Patients with Rheumatoid Arthritis: A Cohort 
Study,” by Krieckaert et al. (2012) when they state: 
Generalized bone loss in osteoporosis goes beyond localized, periarticular bone 
loss in the affected joints. It is assumed that generalized and local bone loss share 
a common, inflammation-driven pathway, in which receptor activator of nuclear 
factor-B (RANKL) plays an important role (1).
 Krieckaert et al . illustrate how TNF factors bind to RANKL to actively 
cause inflammation in the joints. This inflammation occurs when RANKL is 
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activated, and causes the production of osteoclasts. These osteoclasts then at-
tack the bones and cartilage, breaking up the organic bone  located there, caus-
ing inflammation as a result. In addition, Ouyang et al. stated that increasing 
TNF-α would “activate and damage the local vascular endothelial cells (VECs) 
to increase their permeability, and aggravate the local tissue inflammatory ede-
ma and infiltration” (505). The research presented by Bai et al., Krieckaert et al. 
and Ouyang et al. suggests that if TNF factors were decreased, there would be 
a decrease in osteoclast production since RANKL would be activated in smaller 
amounts. 
 The above research  discussed TNF’s role as a ligand for RANKL; however, 
there is another chemical that acts as an antagonist to RANKL. Four and half 
LIM domain 2 (FHL2) also binds with RANKL, like TNF, except instead of ac-
tivating RANKL, it inhibits it, thereby acting as a receptor antagonist. Bai et al. 
explain that:
 Four and half LIM domain 2 (FHL2) is a LIM domain-only protein, not 
present in bone marrow macrophages (BMMs) but induced by RANKL, which 
binds TRAF6, thereby inhibiting its interaction with RANK (6). 
The inhibition of RANKL therefore stops the body’s production of osteoclasts, 
which leads to the inhibition of osteoclast attack and destruction on the patient’s 
joints. Thus, the inhibition of RANKL may cause a reduction in inflammation. 
Consequently, FHL2 and RANKL have an indirect relationship. This means that 
in order to find a way to decrease inflammation through the RANKL pathway, 
either TNF factors must be reduced or FHL2 factors must be increased. Either 
mechanism will result in a decreased activation of RANKL, which will lead to a 
reduction in the number of osteoclasts that are produced by the body.  
Prescription Drug Treatment of Rheumatoid Arthritis
 When a patient is diagnosed with RA, the most common treatment meth-
od for the pain and inflammation is a prescription anti-TNF drug. One of the 
most common drugs on the market is Humira, in which its leading ingredient 
is the anti-TNF drug, adalimumab. However, Humira has many adverse effects. 
The side effects of this drug range from “headache, stuffy nose, sinus pain, [and] 
mild stomach pain” (Physicians’ Desk Reference 1), to a reduced immune sys-
tem, which has caused some patients to develop skin lesions, lymphoma, allergic 
reactions, and the inability to form blood clots. The Food and Drug Administra-
tion (FDA) warns users on Humira’s prescription guidelines that “liver problems 
can happen in people who use TNF-blocker medicines. These problems can lead 
to liver failure and death” (3196923). 
 Currently, according to the Physician’s Desk Reference (PDR) (2012), 
“Humira is indicated for reducing signs and symptoms, inducing major clinical 
response, inhibiting the progression of structural damage, and improving phys-
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ical function in adult patients with moderately to severely active rheumatoid 
arthritis” because of its role of treating RA’s inflammation and joint pain (1). 
Binder et al. in, “TNF Inhibiting Therapy Preferentially Targets Bone Destruc-
tion but Not Synovial Inflammation in a TNF Driven Model of Rheumatoid 
Arthritis,”  state that Humira works to lower the TNF that causes inflammation 
to occur because the inflammation is:
Retarded, by treatment with the anti-TNF antibody infliximab, even if clinical 
signs and symptoms of inflammation are not affected. Similar observations have 
been also made for two other TNF inhibitors, etanercept and adalimumab [Hu-
mira] (611).
 The findings by Binder et al. are supported by their research that they 
conducted on the use of the anti-TNF drug Humira, and how it affected the os-
teoclast (OC) numbers that are found in the body.  This is relevant because when 
TNF activates RANKL, osteoclasts are produced in the bone, therefore when 
OC numbers decrease, TNF levels are being lowered. The conclusion by Binder 
et al. was:
 We found that TNF inhibition dramatically reduced pre-OC numbers in 
a dose depended manner [figure 1, B]. Moreover, TNF inhibition was effective 
in reducing pre-OC numbers not only in the absence, but even in the presence 
of RANKL [figure 2 D]. Taken together these data suggest that TNF inhibition 
mainly affects pre-OC differentiation rather than the development of mature 
OCs, at least under these conditions (611).
Figure 1 B: “Use of different concentrations of Humira on pre-OC numbers. 
Figure 1 D: “Effect of TNF inhibition of pre-OC numbers” (Binder et al. 611).
Since TNF inhibitions only affect pre-OCs, this means that prior OC’s in the 
body will continue to be present and harm the joint. Humira, will stop any new 
OC’s from forming, decreasing inflammation over time. When OC’s are formed, 
they attack the bone and cartilage in the joints resulting in decreased bone mass 
density (BMD), as in Rheumatoid Arthritis patients. This was supported by 
Krieckaert’s et al. because they found that the “mean BMD change per year was 
0.58% and 0.07% for the hip and lumbar spine, respectively, during a mean 
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follow-up period of 4 years” in experiments done with Humira (3). Therefore, 
the anti-TNF drug, Humira, helps decrease the OC production and retard the 
BMD loss in patients  
Side-effects of Humira
 Humira has many benefits, as well as many negative side effects such as 
a decrease in immune system functioning and an increased risk of cancer, liver 
disease, and heart failure. Although all of these side-effects are not experienced 
by over 50% of the patients that take Humira, common side-effects include 
“headache, stuffy nose, sinus pain, mild stomach pain; or pain, redness, itching, 
swelling, or bleeding where you injected the medication” (Physician’s Desk Ref-
erence 1). These common side effects, although less serious, can still be crippling 
to the daily activities of a patient. According to the National Institute of Health 
(NIH) “common adverse reactions (incidence >10%): infections (e.g. upper re-
spiratory, sinusitis), injection site reactions, headache and rash” are prevalent in 
RA patients (1). Although these reactions are not life threatening, they do cause 
the patient discomfort, and should be taken into consideration when taking Hu-
mira.  The side-effects that are life-threatening should not be taken lightly, since 
they are more likely to occur in patients that are older and already have a serious 
infection such as Crohn’s disease or heart disease.
 The most problematic of these effects is the suppression of the patient’s 
immune system. According to the Physician’s Desk Reference (PDR), “patients 
treated with Humira are at increased risk for developing serious infections that 
may lead to hospitalization or death,”  causing thousands of Humira patients 
to take other drugs to cure infections that they contract while on Humira  (1). 
This risk of infection is supported by the Food and Drug Administration because 
“serious infection…even if your TB test is negative your doctor should carefully 
monitor you for TB infections while you are taking HUMIRA ” (Food and Drug 
Administration 3196923). This suggests that it is easier for a patient to contract 
tuberculosis while taking Humira. The risk of serious infection is important be-
cause many of the patients who are prescribed Humira are older, and already 
have a suppressed immune system. This means that for older adults, whom often 
are characterized by more compromised immune  systems, may be at increased 
risk of contracting diseases such as “Tuberculosis (TB), invasive fungal, and oth-
er opportunistic infections, some fatal,” according to the National Institute of 
Health’s highlights of prescribing Humira information (2007 1). According to 
the PDR, “active tuberculosis (TB), including reactivation of latent TB…Inva-
sive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, 
aspergillosis, blastomycosis, and pneumocystosis… [and] bacterial, viral and oth-
er infections due to opportunistic pathogens, including Legionella and Listeria,” 
are repeatedly found in patients who are taking Humira, (1). 
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 The diseases mentioned above, such as TB and fungal infections, may de-
velop fairly quickly after taking Humira. In addition, Humira  can cause cancer, 
which most likely will not develop in susceptible patients until after the patient 
has ceased taking Humira. This is supported in a study in “Lymphomatoid Pap-
ulosis in a Patient Treated with Adalimumab for Juvenile Rheumatoid Arthritis,” 
by Park in which the researchers stated that “TNF- blockers [including adalim-
umab/ Humira] used to treat inflammatory disorders are also believed to reduce 
host immune responses to malignancy, thereby indirectly increasing the risk of 
secondary cancers ” (261). In Park’s study, he also found that “to date, data from 
several studies and case reports have shown an increased incidence of lymphoma 
in patients treated with anti-TNF agents” (259 ). These cases of lymphoma are 
supported by the NIH (2007) in their prescription data when they state, “Ma-
lignancies are seen more often than in controls, and lymphoma is seen more 
often than in the general population” (1), and further supported by the FDA 
who found that besides lymphoma, other cancer such as “basal cell cancer and 
squamous cell cancer of the skin [occur in the patient]. These types of cancer are 
generally not life-threatening if treated but “people with RA, especially more seri-
ous RA, may have a higher chance for getting a kind of cancer called lymphoma” 
(3196923).  
  This is important because according to 
the PDR (2012) “Humira is indicated for 
reducing signs and symptoms, inducing 
major clinical response, inhibiting the 
progression of structural damage, and 
improving physical function in adult pa-
tients with moderately to severely active 
rheumatoid arthritis,” (1) and is there-
fore commonly prescribed to people with 
Rheumatoid Arthritis . However, Humi-
ra directly “increases your change of hav-
ing a higher chance for getting a kind of 
cancer called lymphoma”  (Physician’s Desk Reference 3196923). Furthermore:
 “Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a 
rare type of T-cell lymphoma, have been reported in patients treated with TNF 
blockers including Humira. These cases have had a very aggressive disease course 
and have been fatal” (Physician’s Desk Reference 1). 
 This means that by taking Humira, it is possible to contract strains of rare 
forms of lymphoma which ca n cause death because little knowledge is known 
about the cancer’s treatment and its inability to cure it.  
 Besides cancer, there are other side-effects that are prevalent with the use 
of Humira.  The liver is an important organ in the body because of its functions 
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Figure 2: “Erthematous to brown 
nodules on the elbow and upper 
arm.” (Park 260)
of cleaning the blood, regulating blood clots, and producing bile. Humans are 
therefore unable to survive without a functioning liver.  Thus, it is a problem 
that the FDA (2012) found that “liver problems can happen in people who use 
TNF-blocker medicines [Humira ]. Thes problems can lead to liver failure and 
death”  (3196923). By taking Humira, patients are at risk of liver damage, which 
is deleterious to normal liver functionality. In addition, another problem associ-
ated to Humira is “heart failure, worsening or new onset”  (National Institute of 
Health 1). As a result, Humira should not be a choice drug for those people who 
already have heart disease or who are at risk of heart disease.    
 Furthermore, Humira is expensive,  costing a patient without insurance 
coverage around $4,507.36 a year because Humira is usually prescribed “usually 
every other week” (Food  and Drug Administration 1). However, after receiving 
a prescription from your doctor, Humira can be mailed to your home, or picked 
up at any local pharmacy, making it easily accessible to almost any person in the 
United States as long as they can pay for the dosages . This suggests that Humira 
should be used as a first choice of treatment for patients who are home-bound or 
sedentary because they cannot receive treatments such as cupping or acupunc-
ture, which require patients to go to outside-of-home facilities. However, for RA 
patients who are not restrained due to a sedentary lifestyle,, they should consider 
alternative treatment methods before resorting to Humira to prevent the poten-
tial onset of Humira induced disease. 
How Electro-Acupuncture Works
 Electro-acupuncture reduces inflammation caused by Rheumatoid Arthri-
tis because it targets the TNF levels in the peripheral blood and  the joint fluid,, 
thereby lowering TNF levels in the body and reducing joint inflammation. 
 Acupuncture has been used to treat pain and inflammation in people since 
the second century B.C.E. In the research paper, “Influence of Electroacupunc-
ture on Tumor Necrosis Factor-α and Vascular Endothelial Growth Factor in 
Rats with Experimental Arthritis”, Jie et al. (2012)  found that:
Due to the universality and network profile of the cytokines in the pathological 
process of RA, the pathway for EA [electro-acupuncture] effect on TNF-α and 
VEGF reduction might be as the following four: the first is a direct inhibitory 
effect; the second is indirect inhibition, i.e., through the cytokines mutual cou-
pling effect; the third is the role of chemokine generation; the last is the regula-
tory function of nerve-immune-endocrine system (208).
 Jie et al.  suggest that EA has a direct effect on the amount of TNF in the 
body.  This claim is supported by his experiments,  which showed that “syno-
vial content were insignificantly different after treatment (P>0.05), suggesting 
the equivalent effects of EA and SN in lowering TNF-α contents” (3). Because 
TNF factors were lowered due to EA, this means that less RANKL was activated, 
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which resulted in a decrease in osteoclast production. This would lead to a de-
crease in inflammation, which was proven by a “reduction of stimulation caused 
by antigen in the whole body and local inflammation” (Jie et al. 207). 
 
Table 1: “Comparison of TNF-α Contents in Blood and Synovia” (Ouyang 507).
 Furthermore, in “Effect of Electro-acupuncture on Tumor Necrosis Fac-
tor-α and Vascular Endothelial Growth Factor in Peripheral Blood and Joint 
Synovia of Patients with Rheumatoid Arthritis,” Ouyang et al. (2011)  described 
their patients as having “high acceptance,” referring to the fact that their patients 
had no or minimal discomfort with electro-acupuncture, and therefore did not 
stop treatment (508). “High acceptance” is important because, as a viable treat-
ment for inflammation, EA must be used on as many different types of people 
with varying diseases and pain tolerance levels. The discomfort consisted of nau-
sea or small tingling pain where the needle was injected. Ouyang et al.  also ob-
served that there was not any “adverse reaction related with the treatment [that] 
occurred during the observation period,”  thus concluding that no allergic reac-
tions or major health issues occurred (508). The one caveat to electro-acupunc-
ture is that blood diseases could be passed between people who shared needles. 
Therefore, when receiving electro-acupuncture, it should be done in a medical 
facility that uses safe disposal and cleaning methods for objects that contact bodi-
ly fluids.
 In terms of cost, the amount of money per week for acupuncture is dras-
tically lower than paying for Humira, with “sessions with an acupuncturist run-
ning about $65 to $120, depending on where you live” (Alderman B5). With 
even the most expensive treatments costing $300 a session, this corresponds to 
only $3600 a year, an amount still about $1,000 less than Humira treatment. 
However, many “acupuncture schools have clinics where you can be treated by 
supervised students at discounted rates of $40 or so for one to two hours” (Al-
derman B5), which would decrease the costs of having acupuncture performed. 
These schools are located within every state of the United States, including some 
territories, and most offer reduced prices when students are performing the acu-
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puncture. Therefore, if the patient has access to transportation, it is more likely 
that he or she can find a school that is sponsored by the American Association of 
Acupuncture and Oriental Medicine. There, the patient is able to receive cheaper 
acupuncture treatment, and therefore acupuncture should be considered as a 
treatment when compared to the prescription drug Humira. 
How pulsatile dry cupping works
 Pulsatile dry cupping is one way to treat Rheumatoid Arthritis patients 
because it can stimulate deep into the skin, affecting the acupuncture points, 
releasing chemicals in the body which will decrease the levels of TNF and inflam-
mation 
 According to M. Teut et al . in “Pulsatile Dry Cupping in Patients with 
Osteoarthritis of the Knee – A Randomized Controlled Exploratory Trial,”  cup-
ping also comes in two different forms, dry and wet. Today, the most common 
form, and the one used in this study, is pulsatile dry cupping . Pulsatile dry 
cupping “is a modernized technology using a mechanical device that generates a 
pulsatile vacuum with a pump,” when the vacuum is applied to the area that has 
pain with a cup (2). 
  By using modeling, Tham et al. 
in “Cupping: From a Biomechan-
ical Perspective,” the researchers 
found that the stresses on the skin 
that are caused by the pulsatile dry 
cupping were found at:
 The center of the cup (r ¼ 0 mm) 
and the compressive stresses just 
beyond the rim of the cup ðrX25 
mmÞ are increased for increasing 
vacuum pressure loads. For the 
vacuum pressures applied, the re-
sults also show that the effect of cupping does not extend beyond the area en-
closed by the cup; at twice the cup diameter ðr ¼ 50 mmÞ, the stresses at the 
fat-muscle interface are negligible (2188).
 This pressure will ultimately cause the decrease in inflammation in the 
affected joints that the cupping is being applied to. Teut et al.  postulated that 
“the level of the spinal cord may also be involved [in reduction of pain]: Manip-
ulations may stimulate inhibitory receptive fields of the multi-receptive dorsal 
horn neurons” (8). Tham et al. further supported this theory because according 
to their theory:
 AA (Acupuncture analgesia) is initiated by the stimulation of the small 
diameter nerves in muscles which then send impulses to the spinal cord. The 
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Figure 3: “Application of adaptable sili-
cone cup at the knee” (Teut et al. 4).
three neural centers, namely, the spinal cord, the mid-brain, and the pituitary are 
subsequently activated and release transmitter chemicals, such as endorphins and 
monoamines, which block the pain messages (2184).
 This illustrated that the chemicals released by the Central Nervous System 
could act like FHL2, and act as antagonist to RANKL. This would inhibit the 
formation of osteocytes, which would then lead to the decrease of inflammation 
in a patient’s body.
 While cupping does decrease pain and inflammation overall in the area 
that the cup is being applied to, cupping of all types causes some damage to skin. 
According to Teut et al., cupping “may firstly influence chronic pain locally by 
deforming or even injuring the skin which stimulates Aβ fibers in painful but 
also distal skin regions” (8). This damage to the skin is primarily seen and char-
acterized by Tham (2205) as:
Ecchymosis, a discolouration of the skin caused by the escape of blood into the 
tissue from ruptured blood vessels. This is a characteristic feature of the cupping 
treatment and takes the form of a circular lesion” (2192).
  However, while pulsatile dry cupping 
can cause some skin discomfort through 
bruising, Tham et al. stated that cupping 
has one major advantage in that “trans-
mission of blood-borne diseases can be 
avoided since skin is not penetrated” (2 
191). This makes cupping superior to acu-
puncture and Humira, because in both 
acupuncture and Humira, a needle must 
puncture the skin in order to stimulate 
perform the RA treatment. In contrast, 
pulsatile dry cupping can stimulate acu-
puncture points without puncturing the 
skin, therefore is noninvasive compared to 
by acupuncture and he use of Humira.
 Cupping, like acupuncture, is less ex-
pensive than the cost of the drug Humira. According to the British Acupuncture 
Council, cupping tends to run between “£40[$52.40] to £50 [$65.50] a ses-
sion–lasting from half an hour to 40 minutes. The number of sessions needed 
is determined by the therapist” ( 1). This cost would equate to around $786 per 
year, making cupping the cheapest of the three treatments . However, cupping is 
the hardest of the three options to obtain because it is not wide spread across the 
United States, with only one location in some states. However , due to its low 
cost and only side effect of bruising, pulsatile dry cupping should be an alterna-
tive to Humira.
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Figure 4: “Results of Cupping” 
(Tham et al. 2191).
Conclusion
 From the evidence presented in this research paper, Humira, electro-acu-
puncture, and pulsatile dry cupping treatment all decrease the levels of TNF in 
the human body. This reduction in TNF leads to reduced osteoclast formation 
and therefore a minimization of swelling in Rheumatoid Arthritis patients. How-
ever, due to the various side effects of the treatments, each form of treatment 
should not be considered as equal. 
 When looking at the costs and locations of these three treatments, Humi-
ra and acupuncture are the most expensive and therefore pulsatile dry cupping 
should be the patient’s first option.  The only caveat to this is that cupping is the 
hardest form of treatment to find in the United States. In addition, if the patient 
is house bound , Humira should be the primary form of treatment. In contrast, 
acupuncture would be the easiest to find and is the second cheapest option of 
treatment.
 When looking solely at the patient’s health, Humira should be the last 
remedy to treat the symptoms of RA. While Humira has been proven to lower 
TNF factors and helps many people with inflammation associated with RA, the 
side effects can be life-threatening and potentially life-altering. Any drug that 
is “believed to reduce host immune responses to malignancy, thereby indirect-
ly increasing the risk of secondary cancers” (Park 261),  should not be used by 
the general public. One might argue that the onset of cancer is considered an 
‘uncommon’ side effect, and therefore Humira should still be taken. However, 
“headache, stuffy nose, sinus pain, mild stomach pain” (Physician’s Desk Refer-
ence 1), are common in patients who take Humira and can negatively impact 
a patient’s health and ability to function normally. Furthermore, any drug that 
‘reduces host immune responses’ and will give RA patients a “higher chance for 
getting a kind of cancer called lymphoma”  (Food and Drug Administration 
3196923) can cause side effects that may not appear until after the patient has 
stopped taking Humira.  
 Therefore, the two best options for RA treatment in terms of health for 
the patient are pulsatile dry cupping and electro-acupuncture. This is because 
pulsatile dry cupping may cause, “ecchymosis, a discolouration of the skin caused 
by the escape of blood into the tissue from ruptured blood vessels” (Tham 2192), 
and electro-acupuncture may cause “discomfort consisted of nausea or small tin-
gling pain where the needle was injected” (Ouyang 508), which are byproducts 
that will last only a few weeks, at most. In contrast, the use of Humira can cause 
deleterious effects such as cancers that may last a lifetime. In comparing acu-
puncture to pulsatile dry cupping, pulsatile dry cupping may be better than elec-
tro-acupuncture because there is a greater chance of contracting a blood disease 
from electro-acupuncture since the doctor that administers the treatment must 
pierce the skin in order to perform the treatment whereas pulsatile dry cupping 
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does not involve piercing the skin.
 In conclusion, of the three treatment methods reviewed, Humira is the 
least desirable because it has the worst side effects and also costs the most per 
month. In contrast, both electro-acupuncture and pulsatile dry cupping are sig-
nificantly cheaper than Humira and are safer because they are not associated with 
wignificant long-term side effects. However, between electro-acupuncture and 
pulsatile dry cupping,, cupping is not readily available in the United States and 
thus acupuncture is concluded to be the best method for RA treatment.  
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